Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto of 2004 about 150,000 small farmers had left the countryside; including 50% as of 2009 in the Chaco region. "The Guardian" reported that a Monsanto representative had said, "any problems with GM soya were to do with use of the crop as a monoculture, not because it was GM. If you grow any crop to the exclusion of any other you are bound to get problems." In 2005 and 2006, Monsanto attempted to enforce its patents on soymeal imported into Spain from Argentina by having Spanish customs officials seize the soymeal shipments. This has been an attempt made by Monsanto